Quotient Sciences, CPI Form RNA Drug Development Joint Venture 

Quotient Sciences, a global drug development and manufacturing accelerator, and UK technology innovation centre, CPI, have signed a memorandum of understanding (MoU) to form a Joint Venture (JV) aimed at accelerating the development of RNA-based therapies. Details of the joint venture including name, branding, and operational roadmap will be announced as the collaboration progresses.

The JV will combine Quotient Sciences’ Translational Pharmaceutics platform with CPI’s expertise in small scale manufacture of RNA and LNP encapsulation to deliver an integrated offering for the development of mRNA drug products. 

The JV will integrate mRNA synthesis, LNP formulation development, clinical manufacturing, and early-phase clinical testing. The ability to quickly transition from DNA to RNA and into clinical trials aims to shorten timelines and increase the chances of clinical success, by allowing drug developers to adjust dose and formulation parameters based real-time clinical data from healthy human volunteers.   

“This is a pivotal moment for RNA drug development,” said Thierry Van Nieuwenhove, CEO at Quotient Sciences. “The combined innovation and deep technical expertise of Quotient and CPI will enable developers to benefit from a vastly accelerated supply chain, with clinical batches going from plasmid to clinical dose in as little as two months. This offers a highly streamlined pathway to early-phase clinical trials for mRNA drug candidates.”

Frank Millar, CEO at CPI, said, “We’re proud to be partnering with Quotient Sciences on this initiative which represents a bold step forward for the RNA ecosystem. Our shared vision is to enable scalable and sustainable development pathways for mRNA therapies that meet global health challenges head-on.”

Translational Pharmaceutics has been used globally by pharma and biopharma companies on more than 500 programs with small molecule and peptide drug candidates. This JV extends the application of Translational Pharmaceutics into mRNA-based therapeutics.